Close

GTF2A1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Accurate transcription initiation on TATA-containing class II genes involves the ordered assembly of RNA polymerase II (POLR2A; MIM 180660) and several general initiation factors (summarized by DeJong and Roeder, 1993 [PubMed 8224848]). One of these factors is TFIIA, which when purified from HeLa extracts consists of 35-, 19-, and 12-kD subunits.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-WFY0889 Anti-GTF2A1 (CBFYH-2989) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYH-2989 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY4142 Anti-GTF2A1 (CBFYH-2989) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYH-2989 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.